TBX2 Expression predicts Tumor Recurrence and Adjuvant Chemotherapy Benefits in Gastric Cancer Patients following R0 Resection: a proposed approach for risk stratification
Conclusion: TBX2 may be not only a useful prognostic marker for GC but also a predictive biomarker of response to PAC in stage II/III GC patients. The current findings warrant further verification.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Jun Lu, Yu Xu, Yao-hui Wang, Xiao-yan Huang, Yuan Wu, Jian-wei Xie, Jia-bin Wang, Jian-xian Lin, Ping Li, Chao-hui Zheng, Ai-min Huang, Chang-ming Huang Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Study